152 related articles for article (PubMed ID: 25678187)
1. Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma.
Tsimafeyeu I; Bratslavsky G
Oncology; 2015; 88(6):321-31. PubMed ID: 25678187
[TBL] [Abstract][Full Text] [Related]
2. Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.
Massari F; Ciccarese C; Santoni M; Lopez-Beltran A; Scarpelli M; Montironi R; Cheng L
Expert Rev Anticancer Ther; 2015; 15(12):1367-9. PubMed ID: 26568023
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma.
Tsimafeyeu I; Demidov L; Stepanova E; Wynn N; Ta H
Scand J Urol Nephrol; 2011 Apr; 45(3):190-5. PubMed ID: 21329481
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
Sonpavde G; Willey CD; Sudarshan S
Expert Opin Investig Drugs; 2014 Mar; 23(3):305-15. PubMed ID: 24387233
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
[TBL] [Abstract][Full Text] [Related]
6. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
[TBL] [Abstract][Full Text] [Related]
7. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
8. [Molecular targeted therapy for advanced renal cell carcinoma].
Kanayama H
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
[TBL] [Abstract][Full Text] [Related]
9. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
10. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Kats-Ugurlu G; Maass C; van Herpen C; de Waal R; Oosterwijk E; Mulders P; Hulsbergen-van de Kaa C; Leenders W
Histopathology; 2011 Sep; 59(3):562-4. PubMed ID: 22034894
[No Abstract] [Full Text] [Related]
11. Molecularly targeted therapies for renal cell cancer: TRAIL research advances.
Buttyan R; Mian BM
J Urol; 2007 May; 177(5):1606. PubMed ID: 17437767
[No Abstract] [Full Text] [Related]
12. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Kim WY; Kaelin WG
Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
[TBL] [Abstract][Full Text] [Related]
14. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.
Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z
Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700
[TBL] [Abstract][Full Text] [Related]
15. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy in renal cell carcinoma: advancing paradigms.
Posadas EM; Figlin RA
Oncology (Williston Park); 2012 Mar; 26(3):290-301. PubMed ID: 22545314
[TBL] [Abstract][Full Text] [Related]
17. Non-clear cell advanced kidney cancer: is there a gold standard?
Sánchez P; Calvo E; Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
[TBL] [Abstract][Full Text] [Related]
18. Novel tyrosine kinase inhibitors for renal cell carcinoma.
Dorff TB; Pal SK; Quinn DI
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
[TBL] [Abstract][Full Text] [Related]
19. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
[TBL] [Abstract][Full Text] [Related]
20. Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents.
Iacovelli R; DE Tursi M; Mosillo C; Ciardi A; Carella C; Natoli C; Naso G; Cortesi E
Anticancer Res; 2018 May; 38(5):3105-3110. PubMed ID: 29715147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
